Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2012

View Archived Issues

Taisho Pharmaceutical announces new GlyT1 inhibitors

New Exp1 inhibitors show promise in a number of in vitro and in vivo cancer studies

Morphotek evaluates MORAb-004 in new phase II trial

BioAlliance plans phase II Clonidine Lauriad study expansion

FDA requests more information for HyQ BLA

PRINT nanofabrication allows precision synthesis of therapeutic particles

Merck & Co. selects lead from new series of phosphodiesterase 10A inhibitors

Sanofi presents novel oncolytic drug candidate

Preclinical results demonstrate significant early antitumor efficacy of new immunotherapy

Johnson & Johnson reviews progress of first quarter 2012

DFH Pharma and NIH collaborate on development of HIV drugs

Abbott in-licenses Stanford University biomarkers for prostate cancer

Dyax and Eclipse Therapeutics enter licensing agreement

Highly potent and selective EZH2 inhibitors discovered by GSK

Depomed plans NDA filing for Serada

Novel ERK inhibitors designed

Novel PI3Kalpha/mTOR inhibitors developed at Hutchison MediPharma

Exelixis scientists discover new JAK1 inhibitors

New lysophospholipid S1P1 receptor agonists patented

Treatment begins in phase II IMO-3100 trial

Melanoma trial of SCIB-1 clear to advance to phase II

Intellect Neurosciences collaborates with leading Alzheimer's research group

AMRI enters into development and manufacturing deal

ImmunoGen reports advances in its anticancer drug pipeline

GE Healthcare enters Alzheimer's disease collaboration

Confirmatory data support efficacy of Phytopharm ALS candidate drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...